Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 123, 104685
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Servier
This publication has 36 references indexed in Scilit:
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient PlasmaTheranostics, 2017
- Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCROncotarget, 2016
- Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancermemo - Magazine of European Medical Oncology, 2016
- Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)Lung Cancer, 2014
- Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomasEuropean Respiratory Review, 2014
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 2013
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005